ag真人平台官方
Other Affiliated Sites
Simplified Chinese
Traditional Chinese
ag真人平台官方:About Hepalink
ag真人平台官方:Group Profile
ag真人平台官方:Corporate Philosophy
ag真人平台官方:Milestones
ag真人平台官方:Leadership Team
ag真人平台官方:Scientific Advisory Board
Our Businesses
Heparin Business
ag真人平台官方:Global Industrial Chain
ag真人平台官方:Global Heparin Injections Business
Product Profile
ag真人平台官方:CDMO Services
ag真人平台官方:Innovative Drugs
ag真人平台官方:Global Manufacturing
ag真人平台官方:Company News
ag真人平台官方:Investor Relations
ag真人平台官方:Corporate Governance
ag真人平台官方:Disclosures
ag真人平台官方:Stock Information
ag真人平台官方:IR Events
ag真人平台官方:IR Contact
Join Us
ag真人平台官方:Career Development
ag真人平台官方:Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
ag真人平台官方:A-Share Information
ag真人平台官方:H-Share Information
ag真人平台官方:A-Share Information
ag真人平台官方:H-Share Information
2023.12.19
ag真人平台官方：关于联营公司君圣泰医药拟在香港联交所主板上市的公告
2023.12.18
VOLUNTARY ANNOUNCEMENT PROPOSED OFFERING AND LISTING OF SHARES OF HIGHTIDE THERA...
2023.12.18
NOTICE OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING
2023.12.18
PROXY FORM
2023.12.18
NOTIFICATION LETTER
2023.12.18
Circular PROPOSED AMENDMENTS TO THE ARTICLES AND RELATED RULES OF PROCEDURES OF...
2023.12.18
ANNOUNCEMENT PROPOSED AMENDMENTS TO THE ARTICLES
2023.12.18
ag真人平台官方：关于召开2024年第一次临时股东大会的通知公告
2023.12.18
ag真人平台官方：关于修订《公司章程》等相关制度的公告
2023.12.18
ag真人平台官方：第六届董事会第六次会议决议公告
第一页
上一页
6
7
8
9
10
下一页
最后一页
About Hepalink
ag真人平台官方:Group Profile
ag真人平台官方:Corporate Philosophy
ag真人平台官方:Milestones
Leadership Team
ag真人平台官方:Scientific Advisory Board
Our Businesses
ag真人平台官方:Heparin Business
ag真人平台官方:CDMO Services
ag真人平台官方:Innovative Drugs
ag真人平台官方:Global Manufacturing
ag真人平台官方:Company News
Investor Relations
ag真人平台官方:Corporate Governance
ag真人平台官方:Disclosures
Stock Information
ag真人平台官方:IR Events
ag真人平台官方:IR Contact
Join Us
Career Development
ag真人平台官方:Contact Us
Official WeChat Account
ag真人平台官方:Legal Statement
·
ag真人平台官方:Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.
